Famotidine: Partly unmetabolized. No clinical observations pointing to CYP inducing properties. Combined with two inorganic salts without CYP intarective properties

(To be edited, initial data ST OCT 04) Famotidine: Used in ventricular hyperacidity (H2-receptor antagonist). About 70% excreted in urine in unmetabolized form. Partly metabolized in the liver to inactive sulfoxide metabolite. Impaired liver function does not seem to change the kinetics. Famotidine: South African list: use with care. French list: avoid

Uneventful use reported in 1 patient with acute porphyria.